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Purpose: To determine the outcome of part-time occlusion therapy in children with anisometropic amblyopia 
detected after they were 8 years of age. 
Methods: We analyzed 29 eyes with anisometropic amblyopia in children 8 years of age and older. The 
mean age was 8.79±0.98 (range 8~12) years old. The subjects whose best-corrected visual acuity (BCVA) 
did not improve by two lines or better within 2 weeks of wearing glasses full-time were prescribed occlusion 
therapy for 6 hours a day outside of school hours, along with the instruction to wear glasses full-time. 
Subjects who complied with occlusion for more than 3 hours a day were considered to comply well.
Results: The major component of the anisometropia was hyperopia in 51.7% of the subjects, and hyperopia 
plus astigmatism was found in 24.1%. The mean pretreatment BCVA score was 0.51±0.23 (LogMAR). 
Compliance was 89.66%. The mean posttreatment BCVA was 0.03±0.01 (LogMAR), and the success rate, 
based on a posttreatment BCVA of 0.1 (LogMAR) and better, was 96.43%. It took an average of 4.79±3.35 
months to reach the desired posttreatment BCVA. The mean posttreatment stereopsis was 79.78±37.61 
seconds of arc. The recurrence rate was 8%. The visual improvement was related to the degree of 
compliance (p=0.000). The time taken to reach the posttreatment BCVA was shorter in subjects with a better 
pretreatment BCVA (p=0.019), but it did not relate to the compliance (p=0.366).
Conclusions: The most common component of anisometropia detected after 8 years of age was hyperopia. 
The part-time occlusion therapy, which had been carried out after school hours, was successful in most 
cases.  Korean Journal of Ophthalmology 20(3):171-176, 2006
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Amblyopia, which occurs in two percent of the total 
population,
1 is the visual deterioration of one or both eyes 
in the absence of organic abnormalities. It is classified into 
three categories including strabismic amblyopia, aniso-
metropic amblyopia and visual deprivation amblyopia 
according to the cause.
2,3  While strabismic amblyopia has 
commonly been reported to be more than anisometropic 
amblyopia, it was reported that anisometropic amblyopia is 
more common in the case of
 amblyopia detected for the first 
time after 7 or 8 years of age. The reason might be that 
strabismic amblyopia is easier to detect at an earlier date due 
to its manifest strabismus.
4-8  Full-time occlusion has been the 
preferred method of amblyopia treatment, and it has been 
reported that full-time occlusion was more effective in 
anisometropic amblyopia compared with part-time occlusion.
9 
However, full-time occlusion may not be suitable in children 
older than 8 years, considering that they will be attending 
elementary school and should adapt themselves to a group 
environment. In the case of the children undergoing full-time 
occlusion therapy, they might be jeered or shunned by 
classmates and the compliance rate of occlusion therapy 
would likely decrease.
10
The present study focused on researching the clinical 
pattern of anisometropic amblyopia detected for the first time 
at the age of 8 years or older. In the same way, the subjects 
performed part-time occlusion therapy outside of school 
hours in order to determine whether the amblyopia could be 
effectively treated with part-time occlusion therapy in those 
patients.
Materials and Methods
Anisometropic amblyopia, with a difference in best-corrected 
visual acuity (BCVA) of over two lines between both eyes, 
was detected for the first time by a corresponding author in Korean  J  Ophthalmol  Vol.20,  No.3,  2006
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subjects ages 8 years or older after they had entered ele-
mentary school. Anisometropia was defined as the difference 
of spherical equivalent exceeding 0.5 diopters or of astig-
matism exceeding 1.5 diopters.
11 Patients who had not had 
any ophthalmic treatment, who did not show any symptom 
of strabismus, who had never worn glasses before, and whose 
BCVA in their sound eye was 1.0 diopters (LogMAR=0.0) 
were selected. All patients who met the above conditions and 
who had been prescribed the treatment and follow-up 
regimen described below starting in 2000 were included. 
Finally, the subjects were 29 school-aged children. 
An ophthalmic examination including visual acuity, slit- 
lamp biomicroscopy, manifest and cycloplegic refraction, an 
alternate prism cover test, a test of versions/ductions and a 
fundus examination was given in each patient. Cycloplegic 
refractions were performed at 90 minutes after the instillation 
of 1% cyclopentolate eye drops. At the initial prescription, 
full astigmatic refractive errors were corrected and in each 
case spherical diopters were adjusted to the lens power that 
correspond to the patient's best-corrected visual acuity after 
full cycloplegic correction in a trial frame. Every lens power 
over the amblyopic eye was determined by one specialist (a 
corresponding author) and was re-evaluated at each visit and 
whenever there were any changes or new glasses were 
prescribed. Visual acuity was tested with Dr. Hahn's standard 
test chart for 5m, and stereoscopic visual acuity was evaluated 
with the Titmus-fly test and the Randot Stereotest. Near 
stereopsis was graded with normal being 25~60 seconds of 
arc, near normal as 70~100 seconds of arc, and sub-normal 
being over 100 seconds of arc. All visual acuities were 
transposed to the logarithm of the minimal angle of resolution 
(LogMAR) for calculations.
12
If the BCVA did not improve by two lines or better within 
2 weeks after wearing glasses full-time, a 6-hour occlusion 
using a 3 M orthoptic eye patch worn over the sound eye 
combined with a full-time wearing of glasses was prescribed. 
Occlusion was instructed to be done outside of school hours 
and under parental observation. The subject were advised to 
do activities such as watching TV, reading and computer 
operating for at least one hour while their sound eye was 
patched. The subjects were observed at 1-month intervals 
until they achieved their final BCVA, and their parents were 
asked at every visit to report the average occlusion times. 
Compliance was determined by parental reports and those 
who had covered their eyes for over 3 hours a day were 
considered to comply well. 
The period of occlusion therapy was determined by the 
time at which the BCVA reached a plateau of its highest 
level. The patients who had no further changes in visual 
acuity of the amblyopic eye for three consecutive visits after 
attainment of significant improvement were considered to 
reach a plateau. This period did not include the consecutive 
follow-up period after arriving at their plateau or the time 
period during which daily short-time occlusion was continued 
in some patients who complied well in order to maintain the 
achieved final visual acuity (period of maintenance). 
Successful treatment of the amblyopia was defined as cases 
who achieved a posttreatment BCVA of 0.8 (LogMAR=0.1) 
or better.
We also tried to determine if there were any factors 
associated with treatment outcomes in our patients. The 
subjects were divided into three groups according to the 
occlusion time reported by the parents. The first group 
underwent occlusion therapy for 6 hours a day, the second 
group for 4 or 5 hours a day and the third group for 3 hours 
or less daily. Visual improvement was determined by subtrac-
ting posttreatment BCVA (LogMAR) from pretreatment 
BCVA, and the correlation between visual improvement and 
occlusion time was examined. The correlation between 
occlusion time and the period of occlusion therapy was also 
investigated. In addition, to compare means the subjects were 
divided into three groups according to pretreatment BCVA, 
in order of 0.1~0.2 (LogMAR=1.0~0.8), 0.2~0.3 (LogMAR 
=0.7~0.5) and 0.4~0.6 (LogMAR=0.4~0.2). We also examined 
the correlation between pretreatment BCVA and the period 
of occlusion therapy, and between pretreatment BCVA and 
occlusion time.
Statistical analyses were performed including an ANOVA 
test and a Pearson correlation using SPSS (Statistical Package 
for the Social Sciences) for Windows version 9.0. P values 
of less than 0.05 were considered statistically significant.
Results
There were 19 male and 10 females subjects, and their 
mean age was 8.79±0.98 (range: 8~12) years (Table 1). The 
mean follow-up period after the initiation of treatment was 
20.6±17.2 (range: 6~60) months. Mean pretreatment BCVA 
of amblyopic eyes was LogMAR 0.51±0.23 (Table 2). The 
classification types of anisometropia induced myopia plus 
astigmatism in three subjects (10.3%), hyperopia plus 
astigmatism in seven subjects (24.1%), myopia in one subject 
(3.4%), hyperopia in 15 subjects (51.7%) and astigmatism in 
three subjects (10.3%). Hyperopia accounted for the highest 
proportion. 
In two cases visual acuity improved by 1.0 diopter 
(LogMAR=0.0) through simply wearing glasses for one 
month (Table 3). The other 27 cases performed the occlusion 
therapy, and the compliance rate was 88.9% (n = 24/27) (Fig. 
1). As previously mentioned, the subjects were composed of
Age  (year) Subject  (%)
 8
 9
10
12
14  (48.27)
  9  (31)
  5  (17.24)
  1  (3.45)
Total 29  (100)
Table 1. Distribution  of  the  patients’  ages YR  Lee,  et  al.  ANISOMETROPIC  AMBLYOPIA
173
Age (years) /
Gender
Refraction BCVA  of  amblyopic  eye Period  of 
occlusion
(month)
Course  of 
treatment Right  eye Left  eye Pretreatment Posttreatment 
10 / Male +0.75  Dsph +6.5  Dsph 0.1 
(LogMAR=1.0)
discontinued
  9 / Male +2.0  Dsph  -0.75 
Dcyl  170'
Plano  -0.5  Dcyl  180' 0.3 
(LogMAR=0.5)
0.5 
(LogMAR=0.3)
6 ≤3  hours
  8 / Male +3.75  Dsph  -0.25 
Dcyl  180'
+5.5  Dsph  -0.5 
Dcyl  180'
0.6 
(LogMAR=0.2)
1.0 
(LogMAR=0)
- spectacles
  8 / Female +1.5  Dsph  -2.5 
Dcyl  180'
+1.75  Dsph  -5.0 
Dcyl  10'
0.6 
(LogMAR=0.2)
1.0 
(LogMAR=0)
- spectacles
10 / Female +5.5  Dsph  -1.5 
Dcyl  10'
+1.25  Dsph 0.5 
(LogMAR=0.3)
0.8 
(LogMAR=0.1)
9 ≤3  hours
Table 3. This table shows the clinical pattern of the patients who had undergone 3 hours or less of occlusion treatment, 
whose  visual  acuity  was  improved  only  by  wearing  spectacles,  and  also  the  single  subject  who  gave  up  continuing  the 
occlusion  therapy
Fig. 2. Distribution of posttreatment best-corrected visual acuities. 
The  mean  was  LogMAR  0.03±0.01.  The  success  rate  was  93.1% 
based on the cases where the final best-corrected visual acuity w a s 
0.8  (LogMAR=0.1)  or  higher.
Pretreatment  visual  acuity Subject  (%)
0.6  (LogMAR=0.2)
0.5  (LogMAR=0.3)
0.4  (LogMAR=0.4)
0.3  (LogMAR=0.5)
0.2  (LogMAR=0.7)
0.15  (LogMAR=0.8)
0.1  (LogMAR=1.0)
  2  (6.9)
  7  (24.1)
  3  (10.3)
  9  (31.0)
  4  (13.8)
  1  (3.4)
  3  (10.3)
Total 29  (100)
Table 2. Pretreatment best-corrected visual acuities of the 
amblyopic  eyes
Fig. 1. Distribution  of  the  daily  occlusion  hours.  When  subjects 
who  had  covered  their  strong  eyes  for  more  than  3  hours  a  day 
were  considered  to  comply  well,  the  compliance  of  part-time 
occlusion  therapy  was  88.9%.
*: One subject disontinued the occlusion therapy before his corrected 
visual  acuity  reached  the  plateau. 
three groups, the first group of 17 cases (58.62%) underwent 
occlusion therapy for 6 hours a day, the second group of 
seven cases (24.14%) underwent 4 or 5 hours of treatment 
a day, and the third group of two cases (6.9%) underwent 
3 hours or less of occlusion therapy daily. In one case 
(3.45%) the treatment was abandoned and the subject did not 
pursue further occlusion therapy (Table 3).
Mean posttreatment BCVA was LogMAR 0.03±0.01. 
Classification of the posttreatment BCVA showed 1.0 
(LogMAR=0.0) in 22 cases (75.86%), 0.8~0.9 (LogMAR= 
0.1) in five cases (17.24%) and 0.5 (LogMAR=0.3) in one 
case (3.45%). The posttreatment BCVA of one child who 
failed to continue the occlusion was 0.1 (LogMAR=1.0). The 
success rate was 93.1% (n=27/29) (Fig. 2). At the end of the 
period of occlusion therapy, the posttreatment stereopsis was 
examined in 23 cases, and the mean was 79.78±37.61 
seconds of arc. The subjects mostly showed good posttreatKorean  J  Ophthalmol  Vol.20,  No.3,  2006
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Fig. 4. The  period  of  occlusion 
therapy  determined  by  the  time 
at  which  the  pretreatment  best- 
corrected  visual  acuity  reached  a 
plateau of its best level. In most 
cases it took less than 6 months, 
and the mean period of occlusion 
t h e r a p y  w a s  4 . 7 9 ±3.35  months.
Stereopsis Subject  (%)
Normal
Near-normal
Sub-normal
  9  (39.13)
12  (52.17)
  2  (8.7)
Table 4. Distribution  of  posttreatment  stereopsis  in  aniso-
metropic  amblyopes  (Total  subjects=23)
Fig. 3. T h e  g r a p h  o f  m o n t h l y  v i s u a l  a c u i t y  c h a n g e s  a c c o r d i n g  t o  
the  occlusion  time.
ment stereopsis of 100 seconds of arc or better (Table 4). 
Both the pretreatment and posttreatment stereopsis were 
examined in 17 cases. Among those, 14 showed improved 
posttreatment stereopsis, one exhibited a worsened posttreat-
ment stereopsis and two had no change compared with 
preteatment stereopsis. In addition, the BCVA of their sound 
eyes continuously maintained a visual acuity of 1.0 (LogMAR 
=0.0). 
During the follow-up study, two children had a relapse. 
The first child’s BCVA reached 0.9 (LogMAR=0.1) after the 
sixth month of occlusion therapy but had fellen by 0.7 
(LogMAR=0.2) at the 13-month follow-up. This patient's 
BCVA had been maintained at 0.7 (LogMAR=0.2) since 11 
months after the relapse, and her parents did not want to redo 
the occlusion therapy. The second child's BCVA reached 1.0 
(LogMAR=0.0) after the seventh month but fell by 0.6 
(LogMAR=0.2) by the 36th month of follow-up. In this 
second case, the visual acuity returned to 1.0 (LogMAR= 
0.0) after the 6-hour patching was repeated for 2 months. The 
overall relapse rate was 7.96 % (n=2/26). 
Visual improvement and occlusion time showed a signifi-
cantly positive correlation (Pearson correlation coefficient= 
0.566; p=0.001). Statistically significant differences were in 
mean visual improvements between the three classes divided 
by the occlusion time (ANOVA test, p=0.000). The visual 
improvement of the 6-hour group was 0.53±0.22, the 4~ 
5-hour group improved to 0.46±0.22, and the less-than- 
3-hour group was 0.1±0.0 (Fig. 3). 
The mean period of occlusion therapy overall was 4.79±
3.35 months. (Fig. 4) The mean period of occlusion therapy 
in the 6-hour group was 5.31±3.20 months, was 5.00±3.56 
months in the 4~5-hour group, and was 1.00±0.00 month in 
the less-than-3-hour group. However, occlusion time and the 
period of occlusion therapy did not show a significant corre-
lation (Pearson correlation coefficient=0.193; p=0.366) and 
no difference was seen in the mean period of occlusion 
therapy between the three classes when divided by occlusion 
time (ANOVA test, p=0.938). The preteatment LogMAR 
BCVA was positively correlated with the period of occlusion 
therapy (Pearson correlation coefficient=0.442; p=0.019). As 
a result of dividing the pretreatment BCVA into three groups, YR  Lee,  et  al.  ANISOMETROPIC  AMBLYOPIA
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the period of occlusion therapy between the groups showed 
significant differences (ANOVA test, p=0.027). We deter-
mined that the worse the pretreatment BCVA was, the longer 
the period of required occlusion therapy. 
Occlusion time and the pretreatment LogMAR BCVA did 
not show a significant correlation (Pearson correlation coeffi-
cient=0.207; p=0.322). As a result of dividing the pretreat-
ment BCVA patients into three groups, the occlusion time 
between groups did not show differences (ANOVA test, p= 
0.938). 
Discussion
Occlusion of the nonamblyopic eye has been the major 
therapy of amblyopia. Though full-time occlusion has been 
classically used as an effective method, there is no proven 
advantage of longer daily occlusion hours. Opinions vary on 
the number of daily occlusion hours, and there have not been 
conclusions about the most effective and optimal regimen.
13,14 
In addition, Yeom et al.
8 reported that solitary 6-hour 
occlusion therapy revealed an effective improvement of the 
best-corrected visual acuity and provided good maintenance 
of improvement in the treatment for monocular amblyopes 
aged 3 to 8 years. 
PEDIG
15 reported the effectiveness of prescribing 2-hour 
and 6-hour patching in the treatment of strabismic and 
anisometropic amblyopia of a moderate degree in children 
from the ages of 3 to 7 years. Both regimens appeared to 
be equally effective in improving the overall 4-month visual 
acuity. 
There is overwhelming clinical agreement on the concept 
that amblyopia treatment is less effective in older children 
and that amblyopia needs to be treated at an age younger 
than 6 or 7 years.
13,16 Flynn et al.
17 reported that the patient's 
age was the factor most firmly related to a successful result 
in amblyopia treatment. However, whether treatment is really 
ineffective over certain age limits is controversial. Rustein 
and Fuhr
18 and Epelbaum et al.
16 reported that the efficiency 
of amblyopia treatment was substantially poorer in children 
older than 8 to 12 years, and that this efficiency decreased 
as a function of age. However, Oliver et al.
19 reported that 
children over 8 years-old who fully complied with the 
full-time occlusion therapy had an improvement similar to 
that seen in younger patients. Other articles that have 
prescribed full-time occlusion have reported that this regimen 
appears to be effective in improving the visual acuity in these 
older children.
20  The lower treatment efficiency in older 
children might be related to their poor compliance, and good 
results were correlated with good compliance in past 
reports.
19,21 Compliance is the most important factor to derive 
a successful result in occlusion therapy 
22,23, and Noh and 
Cho
24 reported that part-time occlusion is more easily 
practiced than full-time occlusion, which concerns children 
above six years of age. 
We aimed to reduce mental and social problems through 
part-time occlusion therapy taking place outside of school 
hours and targeting school children whose anisometropic 
amblyopia was detected for the first time at the age of 8 
years and older. We also evaluated whether the treatment 
would be effective in this age group. In addition, we strongly 
instructed the parents to cover their children's sound eye 
outside of school hours and to observe their children during 
the occlusion time as much as possible. They were also 
advised to have their children do activities such as watching 
TV, reading or computer operating for at least one hour 
during the occlusion time. Such detailed instructions gave the 
parents a realistic opportunity to adhere to the treatment, and 
its compliance was relatively good at 88.9%.
The success rate in this study was 93.1% based on the 
posttreatment BCVA of LogMAR 0.1 or better. Most 
children showed stereopsis greater than 100 seconds of arc 
at the end of the treatment period. We could not practically 
include a full-time patched group and an untreated control 
group in this study. However the success rate of 93.1% and 
the mean improvement of 0.51 Log MAR unit in our subjects 
was comparable to the results of earlier studies which 
reported that all patients in a full-time occlusion therapy 
group experienced a visual acuity improvement ranging from 
0.12 to 1.0 (mean 0.46) LogMAR units
20 Earlier studies also 
reported that the final vision in 94% of the patients improved 
by at least two lines after full-time occlusion therapy
21, but 
a direct comparison was not possible between these studies 
and the present study because their definition of a successful 
outcome was different from that used in our study. 
Occlusion therapy for unilateral amblyopia is based on 
longstanding clinical experience indicating that a significant 
improvement of visual acuity in the amblyopic eye is rarely 
obtained without sound-eye occlusion due to unbalanced 
retinal rivalry between the two eyes. Even though we could 
not compare our findings with an untreated group, we started 
occlusion therapy only in subjects in which the BCVA did 
not improve by two lines or better after 2 weeks of wearing 
glasses.
The mean period of occlusion therapy was 4.79±3.35 
months and improvement in visual acuity usually occurred 
within 6 months. Improvement was not longer than that of 
other reported studies.
19-21  Oliver et al.
19 reported that during 
the first quarter (0~3 months) of the amblyopia treatment 
there were 3.6 lines of improvement for the oldest group and 
4.1 lines for the youngest group, while relatively minor 
improvements were obtained at later dates. Mohan et al.
20 
reported that the duration required to achieve a stable vision 
improvement had been 5.77, 6.31, 5.27 and 5.22 months in 
patients aged 11, 12, 13 and 14 to 15 years, respectively, 
while Park et al.
21 found that the average treatment duration 
had been 10 months (range of 3~27 months), and improvement 
in visual acuity had mostly occurred in the initial 3~6 months 
of treatment. The occlusion time and the period of occlusion 
therapy did not have a significant relationship (p=0.366) in 
this study. However, it appeared that the patients with the Korean  J  Ophthalmol  Vol.20,  No.3,  2006
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worst pretreatment BCVA scores needed a longer period of 
occlusion therapy (p=0.019).
Visual improvement, which was calculated by subtracting 
the posttreatment LogMAR BCVA from the pretreatment 
LogMAR BCVA, and occlusion time showed a positive 
function of correlation (p=0.001). We think this fact could 
have two aspects in our study subjects. First, the subjects 
who completed longer occlusion hours experienced, a greater 
visual improvement. Because our subjects mostly achieved a 
posttreatment BCVA of over 0.8 (LogMAR=0.2), the greater 
visual improvement roughly means that even though the 
initial visual acuity may have been poor, the compliance rate 
of the subjects was high. Though it is not statistically signi-
ficant (p=0.322), occlusion time and pretreatment LogMAR 
BCVA showed a weakly positive function (Pearson corre-
lation coefficient=0.207), and occlusion time among the three 
classes regarding pretreatment BCVA did not have any 
differences (ANOVA test, p=0.938). The reason for such 
good compliance even in the group with the worst initial 
visual acuity might be that the parents and children could be 
aware of the seriousness of the treatment and were also 
instructed on how to perform the treatment, it might also be 
attributed to a detailed discussion between the physician and 
the patients.
The reported recurrence of treated amblyopia varies in 
articles from 9%
20 to 75%.
18 By PEDIG,
25 in the amblyopes 
younger than 8 years of age who stopped patching, the 
reported relapse rate was 25%, and in those who stopped 
atropine penalization the relapse rate was 21%. The relapse 
rate of 7.96% (n=2/26) in the present study was relatively 
low, and the factors that daily occlusion hours were short and 
the children were older than the usual amblyopia group might 
contribute the lower recurrence but it is necessary to continue 
further studies on amblyopia treatment using large samples 
and control groups to confirm our results. 
Considering the types of anisometropia seen in our 
subjects, the children who had only hyperopia and the ones 
who had hyperopia simultaneously with astigmatism accounted 
for 51.7% and 24.1%, respectively. This showed that the 
anisometropic amblyopia, which was hidden in the children 
over 8 years old, is mostly caused by hyperopia.
In conclusion, the part-time occlusion therapy with at least 
one instructed hour of active visual activity practiced out of 
school hours was effective in anisometropic amblyopes who 
were diagnosed at the age of 8 years and older, and the 
patients complied well with the treatment. Moreover, its 
success rate was not low compared with the full-time 
occlusion. It is expected that the part-time occlusion therapy 
outside of school hours can be effectively used as a therapy 
in relatively older amblyopes.
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